We are excited to announce that the MURDOCK Multiple Sclerosis Study has officially closed out enrollment! Thank you to all of our dedicated MS participants for their support of this landmark research initiative. Follow-up visits for the Primary Progressive MS Study will continue with currently enrolled participants.
Plans are underway to collaborate with the David H. Murdock Research Institute (DHMRI) Analytical Sciences team — also located at the North Carolina Research Campus — to better understand the MURDOCK MS Study team’s preliminary metabolic signature for MS in blood, as well as perform additional analyses to confirm identification of key metabolites in MURDOCK MS biological samples.
Please visit www.DiscoveryMS.org to learn how Duke University and the DHMRI are collaborating to advance MS research using data and samples from the MURDOCK MS Study. The data gleaned through the MS cohort has quickly become an important resource for MS research initiatives. Initial data analysis led to the discovery of a metabolic signature in the serum of participants, which is unique to those with MS.
Goal: Identify biomarkers or “signals” in the brain that can be used to better predict the onset and progression of multiple sclerosis (MS), an inflammatory, autoimmune disease that affects the ability of the brain and spinal cord nerve cells to communicate, resulting in physical and cognitive disability.
Principal Investigator: Dr. Simon Gregory
Study Details: This study enrolled 976 participants, who provided blood and urine samples, a medical questionnaire about general health, and a second questionnaire pertaining to their MS diagnosis. Additionally, 27 participants enrolled in the Primary Progressive MS Study.
In addition to other research, the MURDOCK MS Study team has been working with a replication set of serum samples from the MS cohort and are currently analyzing results. They have recently discovered a promising signature of MS in the serum of study participants not taking MS drugs, as well as relationships between genetic risk variants for MS and metabolite levels in the blood of study participants. This work has the potential to provide insights into how genetic variants increase risk for developing MS.